- In the final data review, prior to the un-blinding of the study data, ResApp identified at least two issues with the clinical data. Contrary to instructions and training, a high number of patients were treated before clinical research staff recorded their cough sounds. A high number of recordings were also found to contain a second person’s cough sounds or an unacceptable amount of background noise and interference. These issues are known to affect cough sound analysis and their presence has skewed these preliminary results.
If this could be done before the unblinding of the study data, why couldn't they monitor the study while it was being done or at least run a test on the procedures before the study occurred and they spent all of this money?
I am hopeful these are merely engineering and procedural issues - but an all mighty cockup.
- Forums
- ASX - By Stock
- RAP
- Ann: Preliminary Top-line Results from SMARTCOUGH-C Study
Ann: Preliminary Top-line Results from SMARTCOUGH-C Study, page-311
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAP (ASX) to my watchlist
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online